Familial hyperchylomicronemia: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{SI}}
{{SI}}
{{CMG}}{{VD}}
{{CMG}}{{AE}}{{VD}}


{{SK}} Type I hyperlipoproteinemia, Burger-Grutz syndrome, primary hyperlipoproteinemia, lipoprotein lipase deficiency, LPL deficiency, idiopathic hyperlipemia, essential hyperlipemia, familial hyperlipemia, lipase D deficiency, hyperlipoproteinemia type IA, familial chylomicronemia, familial lipoprotein lipase deficiency, and familial hyperchylomicronemia.
{{SK}} Type I hyperlipoproteinemia, Burger-Grutz syndrome, primary hyperlipoproteinemia, lipoprotein lipase deficiency, LPL deficiency, idiopathic hyperlipemia, essential hyperlipemia, familial hyperlipemia, lipase D deficiency, hyperlipoproteinemia type IA, familial chylomicronemia, familial lipoprotein lipase deficiency, and familial hyperchylomicronemia.
Line 129: Line 129:


==History and symptoms==
==History and symptoms==
Symptoms of  Type I hyperlipoproteinemia include<ref name="rare diseasediorders">https://rarediseases.info.nih.gov/diseases/6414/hyperlipoproteinemia-type-1 Accessed on 7 November,2016</ref><ref name="pmid23257303">{{cite journal| author=Robinson JG| title=What is the role of advanced lipoprotein analysis in practice? | journal=J Am Coll Cardiol | year= 2012 | volume= 60 | issue= 25 | pages= 2607-15 | pmid=23257303 | doi=10.1016/j.jacc.2012.04.067 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23257303  }} </ref><ref name="medline plus">{{https://medlineplus.gov/ency/article/000408htm}} Accessed on 7 November,2016</ref>.
Symptoms of  Type I hyperlipoproteinemia include<ref name="rare diseasediorders">https://rarediseases.info.nih.gov/diseases/6414/hyperlipoproteinemia-type-1 Accessed on 7 November,2016</ref><ref name="pmid23257303">{{cite journal| author=Robinson JG| title=What is the role of advanced lipoprotein analysis in practice? | journal=J Am Coll Cardiol | year= 2012 | volume= 60 | issue= 25 | pages= 2607-15 | pmid=23257303 | doi=10.1016/j.jacc.2012.04.067 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23257303  }} </ref><ref name="medline plus">{{https://medlineplus.gov/ency/article/000408htm}} Accessed on 7 November,2016</ref>:-
*Abdominal pain (may appear as colic in infancy)
*Abdominal pain (may appear as colic in infancy)
*Loss of appetite
*Loss of appetite
Line 138: Line 138:
*In rare cases, neurological features develop, including depression, memory loss, and mild intellectual decline (dementia).  
*In rare cases, neurological features develop, including depression, memory loss, and mild intellectual decline (dementia).  
==Physical examination==
==Physical examination==
*Signs of Type 1 hyperlipoproteinemia include<ref name="rare diseasediorders">https://rarediseases.info.nih.gov/diseases/6414/hyperlipoproteinemia-type-1 Accessed on 7 November,2016</ref><ref name="pmid23257303">{{cite journal| author=Robinson JG| title=What is the role of advanced lipoprotein analysis in practice? | journal=J Am Coll Cardiol | year= 2012 | volume= 60 | issue= 25 | pages= 2607-15 | pmid=23257303 | doi=10.1016/j.jacc.2012.04.067 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23257303  }} </ref><ref name="medline plus">{{https://medlineplus.gov/ency/article/000408htm}} Accessed on 7 November,2016</ref>:-===
*Signs of Type 1 hyperlipoproteinemia include<ref name="rare diseasediorders">https://rarediseases.info.nih.gov/diseases/6414/hyperlipoproteinemia-type-1 Accessed on 7 November,2016</ref><ref name="pmid23257303">{{cite journal| author=Robinson JG| title=What is the role of advanced lipoprotein analysis in practice? | journal=J Am Coll Cardiol | year= 2012 | volume= 60 | issue= 25 | pages= 2607-15 | pmid=23257303 | doi=10.1016/j.jacc.2012.04.067 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23257303  }} </ref><ref name="medline plus">{{https://medlineplus.gov/ency/article/000408htm}} Accessed on 7 November,2016</ref>:-
**Enlarged liver and spleen
**Enlarged liver and spleen
**Failure to thrive in infancy
**Failure to thrive in infancy
Line 193: Line 193:
==Pregnancy Management==
==Pregnancy Management==
*Pregnant women may experience significant changes in lipid level in second and third trimester, and may require strategies to lower fat intake.
*Pregnant women may experience significant changes in lipid level in second and third trimester, and may require strategies to lower fat intake.
*Al-Shali and colleagues(2002), reported the course and treatment of an 18 yr-old primigravida who had LPL deficiency and hypertriglyceridemia since birth. There experience concluded, that vigilance is required during pregnancy in patients with familial chylomicronemia due to mutant LPL(Gemfibrozil was used in this patient without apparent adverse effects)<ref name="pmid11983347">{{cite journal| author=Al-Shali K, Wang J, Fellows F, Huff MW, Wolfe BM, Hegele RA| title=Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase. | journal=Clin Biochem | year= 2002 | volume= 35 | issue= 2 | pages= 125-30 | pmid=11983347 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11983347  }} </ref>.
*Al-Shali and colleagues(2002), reported the course and treatment of an 18 yr-old primigravida who had LPL deficiency and hypertriglyceridemia since birth. There experience concluded, that vigilance is required during pregnancy in patients with familial chylomicronemia due to mutant LPL<ref name="pmid11983347">{{cite journal| author=Al-Shali K, Wang J, Fellows F, Huff MW, Wolfe BM, Hegele RA| title=Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase. | journal=Clin Biochem | year= 2002 | volume= 35 | issue= 2 | pages= 125-30 | pmid=11983347 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11983347  }} </ref>.
*Comprehensive analysis of risks versus benefits is required before the use of fibrates, nicotinic acid and omega-3 fatty acid<ref name="pmid11983347">{{cite journal| author=Al-Shali K, Wang J, Fellows F, Huff MW, Wolfe BM, Hegele RA| title=Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase. | journal=Clin Biochem | year= 2002 | volume= 35 | issue= 2 | pages= 125-30 | pmid=11983347 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11983347  }} </ref>.  
*Comprehensive analysis of risks versus benefits is required before the use of fibrates, nicotinic acid and omega-3 fatty acid<ref name="pmid11983347">{{cite journal| author=Al-Shali K, Wang J, Fellows F, Huff MW, Wolfe BM, Hegele RA| title=Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase. | journal=Clin Biochem | year= 2002 | volume= 35 | issue= 2 | pages= 125-30 | pmid=11983347 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11983347  }} </ref>.  
===Investigative Therapies===
===Investigative Therapies===
Line 202: Line 202:
*Daniel Gaudet and colleagues(2016), conducted a retrospective study analyzed the frequency and severity of pancreatitis in 19 patients with LPLD up to 6 years after a single treatment with alipogene tiparvovec, and found that  alipogene tiparvovec is associated with a lower frequency and severity of pancreatitis events<ref name="pmid27412455">{{cite journal| author=Gaudet D, Stroes ES, Méthot J, Brisson D, Tremblay K, Bernelot Moens SJ et al.| title=Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis. | journal=Hum Gene Ther | year= 2016 | volume=  | issue=  | pages=  | pmid=27412455 | doi=10.1089/hum.2015.158 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27412455  }} </ref>.
*Daniel Gaudet and colleagues(2016), conducted a retrospective study analyzed the frequency and severity of pancreatitis in 19 patients with LPLD up to 6 years after a single treatment with alipogene tiparvovec, and found that  alipogene tiparvovec is associated with a lower frequency and severity of pancreatitis events<ref name="pmid27412455">{{cite journal| author=Gaudet D, Stroes ES, Méthot J, Brisson D, Tremblay K, Bernelot Moens SJ et al.| title=Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis. | journal=Hum Gene Ther | year= 2016 | volume=  | issue=  | pages=  | pmid=27412455 | doi=10.1089/hum.2015.158 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27412455  }} </ref>.


==Prevention and follow up==
==Prevention==
*There is no way to prevent someone from inheriting this syndrome<ref name="rare diseasediorders">https://rarediseases.info.nih.gov/diseases/6414/hyperlipoproteinemia-type-1 Accessed on 7 November,2016</ref>.
*There is no way to prevent someone from inheriting this syndrome<ref name="rare diseasediorders">https://rarediseases.info.nih.gov/diseases/6414/hyperlipoproteinemia-type-1 Accessed on 7 November,2016</ref>.
*Genetic counseling is recommended for patients and family members as well.
*Genetic counseling is recommended for patients and family members as well.
===Prevention of Primary Manifestations===
===Prevention of Primary Manifestations===
*Maintaining the plasma triglyceride concentration at less than 2000 mg/dL keeps the individual with familial LPL deficiency free of symptoms. This can be accomplished by restriction of dietary fat to no more than 20 g/day or 15% of total energy intake<ref name="medline plus">{{https://medlineplus.gov/ency/article/000408htm}} Accessed on 7 November,2016</ref>.
*Maintaining the plasma triglyceride concentration at less than 2000 mg/dl  keeps the individual with familial LPL deficiency free of symptoms. This can be accomplished by restriction of dietary fat to no more than 20 g/day or 15% of total energy intake<ref name="medline plus">{{https://medlineplus.gov/ency/article/000408htm}} Accessed on 7 November,2016</ref>.
*Periodic assessment of plasma triglycerides levels is higly recommended.
*Periodic assessment of plasma triglycerides levels is highly recommended.
*Patients should avoid agents that increased endogenous triglyceride levels like alcohol, diuretics, oral estrogens, isoretinoin, glucorticords, and beta-blockers.  
*Patients should avoid agents that increased endogenous triglyceride levels like alcohol, diuretics, oral estrogens, isoretinoin, glucorticords, and beta-blockers.  
===Prevention of Secondary Complications===
===Prevention of Secondary Complications===

Revision as of 18:07, 8 November 2016

WikiDoc Resources for Familial hyperchylomicronemia

Articles

Most recent articles on Familial hyperchylomicronemia

Most cited articles on Familial hyperchylomicronemia

Review articles on Familial hyperchylomicronemia

Articles on Familial hyperchylomicronemia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Familial hyperchylomicronemia

Images of Familial hyperchylomicronemia

Photos of Familial hyperchylomicronemia

Podcasts & MP3s on Familial hyperchylomicronemia

Videos on Familial hyperchylomicronemia

Evidence Based Medicine

Cochrane Collaboration on Familial hyperchylomicronemia

Bandolier on Familial hyperchylomicronemia

TRIP on Familial hyperchylomicronemia

Clinical Trials

Ongoing Trials on Familial hyperchylomicronemia at Clinical Trials.gov

Trial results on Familial hyperchylomicronemia

Clinical Trials on Familial hyperchylomicronemia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Familial hyperchylomicronemia

NICE Guidance on Familial hyperchylomicronemia

NHS PRODIGY Guidance

FDA on Familial hyperchylomicronemia

CDC on Familial hyperchylomicronemia

Books

Books on Familial hyperchylomicronemia

News

Familial hyperchylomicronemia in the news

Be alerted to news on Familial hyperchylomicronemia

News trends on Familial hyperchylomicronemia

Commentary

Blogs on Familial hyperchylomicronemia

Definitions

Definitions of Familial hyperchylomicronemia

Patient Resources / Community

Patient resources on Familial hyperchylomicronemia

Discussion groups on Familial hyperchylomicronemia

Patient Handouts on Familial hyperchylomicronemia

Directions to Hospitals Treating Familial hyperchylomicronemia

Risk calculators and risk factors for Familial hyperchylomicronemia

Healthcare Provider Resources

Symptoms of Familial hyperchylomicronemia

Causes & Risk Factors for Familial hyperchylomicronemia

Diagnostic studies for Familial hyperchylomicronemia

Treatment of Familial hyperchylomicronemia

Continuing Medical Education (CME)

CME Programs on Familial hyperchylomicronemia

International

Familial hyperchylomicronemia en Espanol

Familial hyperchylomicronemia en Francais

Business

Familial hyperchylomicronemia in the Marketplace

Patents on Familial hyperchylomicronemia

Experimental / Informatics

List of terms related to Familial hyperchylomicronemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Vishal Devarkonda, M.B.B.S[2]

Synonyms and keywords: Type I hyperlipoproteinemia, Burger-Grutz syndrome, primary hyperlipoproteinemia, lipoprotein lipase deficiency, LPL deficiency, idiopathic hyperlipemia, essential hyperlipemia, familial hyperlipemia, lipase D deficiency, hyperlipoproteinemia type IA, familial chylomicronemia, familial lipoprotein lipase deficiency, and familial hyperchylomicronemia.

Overview

This very rare form is due to a deficiency of lipoprotein lipase (LPL) or altered apolipoprotein C2, resulting in elevated chylomicron which are the particles that transfer fatty acids from the digestive tract to the liver. Lipoprotein lipase is also responsible for the initial breakdown of endogenously made triacylglycerides in the form of very low density lipoprotein (VLDL). As such, one would expect a defect in LPL to also result in elevated VLDL. Its prevalence is one in 1,000,000 population.

Classification

  • Type I hyperlipoproteinemia can be further classified into:

Type 1A

It occurs due to deficiency of lipoprotein lipase enzyme.

Type 1B

Altered apolipoprotein C2 causes type 1B hyperlipoproteinemia.

Type 1C

Presence of LPL inhibitor is the cause of type 1C hyperlipoproteinemia.

Historical Perspective

  • In 1932, Familial LPL deficency was first described by Burger and Grutz[1].

Pathophysiology

  • Type I hyperlipoproteinemia is a rare autosomal recessive disorder of lipoprotein metabolism[2][3][4].

Pathogenesis

  • Lipoprotein lipase(LPL) hydrolysis Triglyceride-rich lipoproteins (TG) such as chylomicrons and very low-density lipoproteins. It catalyzes, the removal of TG from bloodstream generating free fatty acids for tissues.
  • For full enzymatic activity, LPL requires following cofactors:-
    • Apolipoprotein C-II and apolipoprotein A-V that are LPL activators
    • Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein
    • Lipase maturation factor 1
  • Development of Type I hyperlipoproteinemia is the result of the functional mutations in one of all these genes results in type I hyperlipoproteinemia.

Type 1C (Familial lipoprotein lipase inhibitor)

    • Familial lipoprotein lipase inhibitor seems to be inherited as an autosomal dominant trait[5].
    • Presence of familial lipase inhibitor, inhibit the action of lipoprotein lipase, resulting in decreased postheparin plasma LPL activity, elevated adipose tissue LPL activity, and normal plasma levels of functional apoC-I1.
  • Functionally inactive or absent lipoprotein lipase enzyme, results in massive accumulation of chylomicrons, with extremely high level of plasma triglycerides.

Causes

The cause of type 1 hyperlipidemia remains genetic</ref>[6].

Differential diagnosis

Diseases Laboratory Findings Physical Examination History and symptoms other findings
Familial combined hyperlipidemia
Monogenic familial hypertriglyceridemia
Secondary causes of hypertriglyceridemia
Diabetes mellitus
Paraproteinemic disorders
Alcohol usage
Estrogen thearapy
Glucocorticoids
Isotretinoin
Antihypertensive agents

Epidemiology and Demographics

  • Epidemiological and demographics of familial hyperchylomicronemia are discussed below[2][6]:

Epidemiology

  • The disease has been described in all races.
  • The prevalence is much higher in some areas of Quebec, Canada, as a result of a founder effect.
  • The prevalence of familial LPL deficiency is approximately one in 1,000,000 in the general US population.

Demographics

Age

  • 25% of affected children develop symptoms before one year of age.
  • Majority develop symptoms before ten years of age.
  • Few individuals develop symptoms, at the time of pregnancy.

Gender

  • Males and females are equally affected.

Screening

  • There are no screening guidelines for Familial hyperchylomicronemia[6][2][7].
  • Evaluation of Relatives at Risk.It is appropriate to measure plasma triglyceride concentration in at-risk sibs during infancy; early diagnosis and implementation of dietary fat intake restriction can prevent symptoms and related medical complications.

Natural History, Complications, and Prognosis

Natural History

  • If left untreated, pancreatitis can develop into a chronic condition that can damage the pancreas and, in rare cases, be life-threatening[7].

Complications

  • Pancreatitis and recurrent episodes of abdominal pain may develop[7].
  • Xanthomas are not usually painful unless they are rubbed a lot.

Prognosis

  • People with this condition who follow a very low-fat diet can live into adulthood[7].

Diagnosis

  • Presumptive diagnosis can be made, when an infant presents with a history of failure to thrive or recurrent abdominal pain, with an documented high fasting plasma triglyceride concentration[8][7].
  • Diagnosis of familial lipoprotein lipase deficiency is confirmed by detection of low or absent LPL enzyme activity in an assay system that contains either normal plasma or apoprotein C-II excluding hepatic lipase.

History and symptoms

Symptoms of Type I hyperlipoproteinemia include[6][9][7]:-

  • Abdominal pain (may appear as colic in infancy)
  • Loss of appetite
  • Nausea
  • Pain in the muscles and bones (musculoskeletal pain)
  • Vomiting
  • Small yellow papules localized over the trunk, buttocks, knees, and extensor surfaces of the arms
  • In rare cases, neurological features develop, including depression, memory loss, and mild intellectual decline (dementia).

Physical examination

  • Signs of Type 1 hyperlipoproteinemia include[6][9][7]:-
    • Enlarged liver and spleen
    • Failure to thrive in infancy
    • Fatty deposits in the skin (xanthomas)
    • Pale retinas and white-colored blood vessels in the retinas
    • Pancreatitis that keeps returning
    • Yellowing of the eyes and skin (jaundice)

Laboratory finding

  • Laboratory findings consistent with the Type I hyperlipoproteinemia include the following:-
Laboratory finding
Phenotype Lipoprotein(s)

Elevated

Serum total

cholesterol

Serum

triglycerides

Plasma

appearance

Postheparin

lipolytic


activity

Glucose

tolerance

Carbohydrate

inducibility

Fat tolerance
Hyperlipoproteinemia type 1 Chylomicrons Normal to

elevated

Elevated Creamy Decreased Normal May be abnormal Markedly abnormal

Molecular Genetic Testing

  • Diagnosis can be confirmed by molecular genetic testing that can detect mutations in the LPL gene.[2]
  • The test is often not necessary to confirm a diagnosis of LPLD.

Treatment

  • Treatment for hyperlipoproteinemia type 1 is intended to control blood triglyceride levels with a very low-fat diet[6][8] [7].
  • It is recommended that individuals with this condition eat no more than 20 grams of fat per day.
  • Medium-chain fatty acids (such as coconut oil) can be incorporated into the diet, as they are absorbed by the body in a different manner.
  • Dietary counseling may be helpful to maintain adequate calorie and nutrient intake.

Pregnancy Management

  • Pregnant women may experience significant changes in lipid level in second and third trimester, and may require strategies to lower fat intake.
  • Al-Shali and colleagues(2002), reported the course and treatment of an 18 yr-old primigravida who had LPL deficiency and hypertriglyceridemia since birth. There experience concluded, that vigilance is required during pregnancy in patients with familial chylomicronemia due to mutant LPL[10].
  • Comprehensive analysis of risks versus benefits is required before the use of fibrates, nicotinic acid and omega-3 fatty acid[10].

Investigative Therapies

  • Orlistat in conjunction with a low fat diet has been used to treat some patients with compound heterozygous LPLD[11].
  • Blackett and collagues(2013), studied the effect of orlistat in siblings with severe inherited hyperchylomicronemia and to assess posttreatment lipoprotein concentrations and composition, and reported that orlistat can be considered effective in augmenting the effect of a low-fat diet and reducing risk for pancreatitis.

Gene Therapy

  • Alipogene tipavovec(Glybera) gene therapy was approved by European commission(2012), in treating adult patients with recurrent episodes of pancreatitis.
  • Daniel Gaudet and colleagues(2016), conducted a retrospective study analyzed the frequency and severity of pancreatitis in 19 patients with LPLD up to 6 years after a single treatment with alipogene tiparvovec, and found that alipogene tiparvovec is associated with a lower frequency and severity of pancreatitis events[12].

Prevention

  • There is no way to prevent someone from inheriting this syndrome[6].
  • Genetic counseling is recommended for patients and family members as well.

Prevention of Primary Manifestations

  • Maintaining the plasma triglyceride concentration at less than 2000 mg/dl keeps the individual with familial LPL deficiency free of symptoms. This can be accomplished by restriction of dietary fat to no more than 20 g/day or 15% of total energy intake[7].
  • Periodic assessment of plasma triglycerides levels is highly recommended.
  • Patients should avoid agents that increased endogenous triglyceride levels like alcohol, diuretics, oral estrogens, isoretinoin, glucorticords, and beta-blockers.

Prevention of Secondary Complications

  • Prevention of acute recurrent pancreatitis decreases the risk of development of diabetes mellitus. Fat malabsorption is very [7]

References

  1. Template:Http://rarediseases.org/rare-diseases/familial-lipoprotein-lipase-deficiency/Accessed on 7 November,2016
  2. 2.0 2.1 2.2 2.3 Pingitore P, Lepore SM, Pirazzi C, Mancina RM, Motta BM, Valenti L; et al. (2016). "Identification and characterization of two novel mutations in the LPL gene causing type I hyperlipoproteinemia". J Clin Lipidol. 10 (4): 816–23. doi:10.1016/j.jacl.2016.02.015. PMID 27578112.
  3. Young SG, Zechner R (2013). "Biochemistry and pathophysiology of intravascular and intracellular lipolysis". Genes Dev. 27 (5): 459–84. doi:10.1101/gad.209296.112. PMC 3605461. PMID 23475957.
  4. Pasalić D, Jurcić Z, Stipancić G, Ferencak G, Leren TP, Djurovic S; et al. (2004). "Missense mutation W86R in exon 3 of the lipoprotein lipase gene in a boy with chylomicronemia". Clin Chim Acta. 343 (1–2): 179–84. doi:10.1016/j.cccn.2004.01.029. PMID 15115692.
  5. Francis A, Levy Y (2002). "[Chylomicronemia syndrome]". Harefuah. 141 (2): 201–3, 221, 220. PMID 11905095.
  6. 6.0 6.1 6.2 6.3 6.4 6.5 6.6 https://rarediseases.info.nih.gov/diseases/6414/hyperlipoproteinemia-type-1 Accessed on 7 November,2016
  7. 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 7.9 Template:Https://medlineplus.gov/ency/article/000408htm Accessed on 7 November,2016
  8. 8.0 8.1 Template:Https://www.ncbi.nlm.nih.gov/books/NBK1308/ Accessed on 7 November,2016
  9. 9.0 9.1 Robinson JG (2012). "What is the role of advanced lipoprotein analysis in practice?". J Am Coll Cardiol. 60 (25): 2607–15. doi:10.1016/j.jacc.2012.04.067. PMID 23257303.
  10. 10.0 10.1 Al-Shali K, Wang J, Fellows F, Huff MW, Wolfe BM, Hegele RA (2002). "Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase". Clin Biochem. 35 (2): 125–30. PMID 11983347.
  11. Blackett P, Tryggestad J, Krishnan S, Li S, Xu W, Alaupovic P; et al. (2013). "Lipoprotein abnormalities in compound heterozygous lipoprotein lipase deficiency after treatment with a low-fat diet and orlistat". J Clin Lipidol. 7 (2): 132–9. doi:10.1016/j.jacl.2012.11.006. PMID 23415432.
  12. Gaudet D, Stroes ES, Méthot J, Brisson D, Tremblay K, Bernelot Moens SJ; et al. (2016). "Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis". Hum Gene Ther. doi:10.1089/hum.2015.158. PMID 27412455.

Template:WikiDoc Sources